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anolazine: Augmenting the
ntianginal Armamentarium*
ohn A. Cairns, MD, FRCPC, FACC
ancouver, Canada
n January 2006, the Food and Drug Administration (FDA)
pproved ranolazine for use in chronic stable angina follow-
ng the completion of a study mandated under the FDA’s
pecial protocol assessment (SPA) process and reported in
his issue of the Journal (1). This is the first agent from a
ew class of antianginal agents to be approved in almost 25
ears, and its potential widespread use warrants careful
eview of the evidence for benefit and harm.
See page 566
Pharmacologic prophylaxis against angina symptoms cur-
ently involves the use of beta-blockers, calcium antagonists,
nd long-acting nitrates (2,3). The evidence for efficacy is
erived from randomized placebo-controlled trials assessing
eductions of anginal frequency and nitroglycerin consump-
ion, improved exercise test performance, and side effects.
hange in quality of life has not been systematically
valuated for any of these agents (2). Long-term studies
mong survivors of myocardial infarction (MI) and unstable
ngina/non–ST-segment elevation MI have shown a reduc-
ion of subsequent coronary events with beta-blockers but
ot with calcium antagonists or long-acting nitrates (2). A
eta-analysis of comparative studies (the majority of them
efore the release of amlodipine and felodipine) found that
eta-blockers compared with calcium antagonists were as-
ociated with significantly fewer episodes of angina per
eek, but there was no significant difference in exercise time
4). Adverse events were significantly less frequent with
eta-blockers, but this difference was confined to nifedipine.
n the relatively few trials comparing beta-blockers or
alcium antagonists to long-acting nitrates, no significant
ifferences were found, although there were trends in
itroglycerin use favoring beta-blockers and in angina epi-
odes favoring calcium antagonists.
It is generally recommended, based on reasonable evi-
ence, that combinations of agents from 2 or even all 3 of
hese drug classes be used in persistently symptomatic
atients (2). Nevertheless, as many as 5% to 15% of the
stimated 6,500,000 Americans with stable angina may be
efractory to even triple therapy and yet not considered
uitable for revascularization (5,6). It is likely that many
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thep
merican College of Cardiology.
From the University of British Columbia, Vancouver, Canada.ore experience undesirable side effects on currently avail-
ble therapies, particularly in combination, and might ben-
fit from an alternative agent. Accordingly, great interest
ttends the evaluations of novel antianginal agents.
Ranolazine is an orally active piperazine derivative,
hich, compared with placebo, reduces angina frequency
nd nitroglycerin consumption and improves exercise test
erformance (7,8). Its efficacy is similar to that of atenolol
9), and is modestly incremental when added to standard
onotherapy with atenolol, diltiazem, or amlodipine (10).
anolazine is well tolerated; the principal side effects in-
lude dizziness, nausea, asthenia, constipation, and head-
che (7,11). Of concern is its propensity to dose-related
rolongation of the QTc, the net effect of its inhibition of
Kr, late INa, and late ICa (7). However, there has been no
vidence of increased dispersion of repolarization nor any
ocumented cases of torsades de pointes. Ranolazine is
etabolized in the liver and excreted in the urine and is
ontraindicated with hepatic impairment. It is metabolized
rimarily by CYP3A, which is potently inhibited by dilti-
zem and verapamil, neither of which should be used
oncurrently. Ranolazine inhibits metabolic pathways for
imvastatin and digoxin, and dose reductions of these agents
ay be required (11).
The antianginal effects of ranolazine are not dependent
n reduction of heart rate or blood pressure or on increases
f coronary blood flow. During exercise testing, patients are
ble to achieve an increased rate-pressure product at maxi-
al exercise compared with placebo or beta-blocker (9).
he mechanism of action of ranolazine is not understood,
ut the agent is a known inhibitor of myocardial fatty acid
xidation, resulting in preferential glucose oxidation (7).
he glucose pathway requires less oxygen for a given level of
yocardial work, and this increased “oxygen efficiency” may
e an important component of the anti-ischemic action.
The ERICA (Efficacy of Ranolazine in Chronic Angina)
rial (1) was well designed, assembling a group of 565
atients (97% from centers in Eastern Europe) who satisfied
ppropriate exclusion criteria, and who continued to have at
east 3 episodes of angina per week while under observation
or a 2-week qualifying phase despite taking 10 mg/day
mlodipine (8). Amlodipine was maintained throughout the
ubsequent trial, as were long-acting nitrates in 45% of
ubjects. There were 564 patients randomized double-blind
o 500 mg ranolazine twice daily for 1 week followed by
,000 mg twice a day for 6 weeks or to placebo. In each
roup, 98% of patients completed the trial. Ranolazine
ignificantly reduced the frequency of angina episodes (pri-
ary efficacy variable) and improved the secondary efficacy
ariables of nitroglycerin consumption and the anginal
requency component of the Seattle Angina Questionnaire
SAQ). (12). There were no important hemodynamic
hanges or other side effects. In conjunction with previous
ata on the antianginal efficacy of ranolazine compared with
lacebo or atenolol and when added to atenolol, diltiazem,
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August 1, 2006:576–8 Editorial Commentr amlodipine, the results satisfied the FDA that ranolazine
ffers incremental benefit over current standard therapies.
What is the clinical importance of the statistically signif-
cant reductions of angina frequency and nitroglycerin
onsumption by ranolazine? Issues to consider include: 1)
he modest reductions in angina frequency and nitroglycerin
onsumption; 2) the absence of statistically significant
ifferences in quality of life measures beyond angina fre-
uency; and 3) the lack of comparison to combination
herapy with beta-blockers and amlodipine.
Exercise test parameters have been extensively used in the
valuation of antianginal agents, because they are objective
nd continuous and allow relatively small sample sizes.
uite modest increases in exercise duration in the range of
0 s to 60 s, have been sufficient to claim efficacy of new
gents alone and in combinations with established therapies
13,14). Reduced angina frequency and nitroglycerin con-
umption may be more relevant to patients and were chosen
s the outcome measures in the ERICA trial. Ranolazine
ecreased angina frequency by only 0.43 episodes per week
ompared with placebo and reduced nitroglycerin consump-
ion by 0.65 tablets per week. However, these differences are
ot out of line with the modest (13,15) improvements or no
hange (14) observed in previous studies of new antianginal
gents in combination regimens. The changes on placebo
lone between baseline and 6 weeks of angina frequency
2.47 fewer episodes per week) and nitroglycerin consump-
ion (2.34 fewer tablets per week) were several times greater
han the differences between placebo and ranolazine, a
eminder of the importance of placebo controls. Similar
bservations of placebo effect have been made in earlier
rials of antianginal drugs (10,13).
In short-term trials of low-risk patients, major clinical
utcomes will not differ, and therefore improvements of
ractical importance to patient function should be sought.
herefore, the use of the SAQ (12), a disease-specific
easurement of quality of life, is an appealing design feature
f the ERICA trial. Although the SAQ domain of anginal
requency showed a statistically significantly greater reduc-
ion by ranolazine consistent with the major outcome of the
tudy, the differences in the other 4 domains were not
ignificant. Accordingly the clinical importance of the im-
rovement in the study’s primary efficacy variable remains
ncertain.
Current guidelines recommend combinations of beta-
lockers, calcium antagonists, and long-acting nitrates in
ppropriate patients (2,3). Ranolazine’s absence of hemody-
amic effects suggests theoretically attractive alternative
ombinations. Studies should be done to compare the
ddition of ranolazine versus beta-blocker in patients al-
eady taking amlodipine and the addition of ranolazine
ersus amlodipine in patients already receiving a beta-
locker. In patients receiving a beta-blocker and amlodip-
ne, the addition of ranolazine versus placebo should be
valuated. Quality of life measures would be ideal compo-
ents of such studies.Because ranolazine prolongs the QTc, the FDA approval
s limited to patients who have not responded to other
ntianginal drugs, and its use in combination with amlo-
ipine, beta-blockers, or long-acting nitrates is recom-
ended. The daily dose should be limited to 1,000 mg and
recautions are advised regarding QTc prolongation. Post-
elease surveillance and additional studies with larger sample
izes and longer durations are essential to assist in deter-
ining whether ranolazine’s side effects, including prolon-
ation of QTc, are sufficiently rare and minor to eventually
arrant its use as a primary therapy. Additional studies
hould be done to determine whether the addition of
anolazine to standard monotherapies and combinations is
quivalent or superior to the addition of current agents.
uality of life measures allowing comparisons of greater
linical relevance to individual patients have led to clinically
elevant conclusions in studies of invasive therapies (16–18),
ut have been woefully lacking in drug evaluations. The use
f a disease-specific measure of quality of life, as in the
RICA trial, should be seriously considered in the design of
ew trials of antianginal drugs.
eprint requests and correspondence: Dr. John A. Cairns, Jim
attison Pavilion North, Room 3150, Vancouver General Hospi-
al, 910 West 10th Avenue, Vancouver, BC, Canada V5Z 4E3.
-mail: jacairns@medd.med.ubc.ca.
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